The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonitis are progressive interstitial lung diseases (ILDs) with limited treatment options and poor survival. However, the rate of disease progression is variable, implying there may be different endotypes of disease. We hypothesised that immunophenotyping biopsies from ILD patients might reveal distinct endotypes of progressive fibrotic disease, which may facilitate stratification when undertaking clinical trials of novel therapies for IPF. 43 paraffin-embedded, formalin-fixed lung tissue sections were immunostained for five molecules implicated in the pathogenesis of the fibrosis: α-smooth muscle actin (αSMA), αvβ6 integrin, pro-surfactant protein C (SP-C), hepatocyte growth factor (HGF) and tenascin-C (TenC). Levels of immunostaining and numbers of fibroblastic foci were quantified using operator-dependent and -independent methods. The relationship of all these markers to overall survival was analysed. Staining revealed high levels of αSMA, αvβ6 integrin, pro-SP-C, HGF and TenC, and fibroblastic foci. Immunostaining varied across samples for all molecules but only the extent of αvβ6 integrin immunostaining was associated with increased mortality. There was no association with the other markers measured. Our data suggest high levels of αvβ6 integrin may identify a specific endotype of progressive fibrotic lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“αvβ6 levels are increased in lung tissue from IPF patients and correlate with poorer prognostic outcomes, so that this integrin might also hold prognostic value (Saini et al., 2015).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Saini et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,651
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Histopathologic Variability in Usual and Nonspecific Interstitial Pneumonias
FLAHERTY, K. R., Travis, W. D., Colby, T. V., Toews, G. B., Kazerooni, E. A., Gross, B. H., Jain, A. K., Strawderman, R. L., Flint, A., Lynch, J. P., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103074 · Cited by 666
King, T. E., Schwarz, M. I., Brown, K. M., Tooze, J. A., Colby, T. V., Waldron, J. A., Flint, A., Thurlbeck, W. M., & Cherniack, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 629
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 582
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK
Gribbin, J., Hubbard, R., Jeune, I. L., Smith, C. J. P., West, J., & Tata, L. J. (2006) · Thorax · doi:10.1136/thx.2006.062836 · Cited by 574
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · CHEST Journal · doi:10.1378/chest.06-2568 · Cited by 538
The rising incidence of idiopathic pulmonary fibrosis in the UK
Navaratnam, V. V., Fleming, K. M., West, J., Smith, C. J. P., Jenkins, G. R., Fogarty, A., & Hubbard, R. (2011) · Thorax · doi:10.1136/thx.2010.148031 · Cited by 484
Self-citationPartial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Self-citation
Cited by
Sorted by citations
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, G. R., & Hatley, R. J. D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 558
Self-citationJenkins, G. R., Moore, B. B., Chambers, R. C., Eickelberg, O., Königshoff, M., Kolb, M. R. J., Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0096st · Cited by 460
Self-citationMaher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
Self-citationThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N. C., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 276
Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history
Sgalla, G., Biffi, A., & Richeldi, L. (2015) · Respirology · doi:10.1111/resp.12683 · Cited by 178
Precision medicine advances in idiopathic pulmonary fibrosis
Karampitsakos, Τ., Juan-Guardela, B. M., Τzouvelekis, Α., & Herazo‐Maya, J. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104766 · Cited by 148
John, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18397-6 · Cited by 131
Self-citationThe extracellular matrix and mechanotransduction in pulmonary fibrosis
Deng, Z., Fear, M. W., Choi, Y. S., Wood, F. M., Allahham, A., Mutsaers, S. E., & Prêle, C. M. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105802 · Cited by 129
Kimura, R. H., Wang, L., Shen, B., Huo, L., Tummers, W. S. F. J., Filipp, F. V., Guo, H. H., Haywood, T., Abou‐Elkacem, L., Baratto, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11863-w · Cited by 120
Bowman, W. S., Newton, C. A., Linderholm, A., Neely, M. L., Pugashetti, J. V., Kaul, B., Vo, V., Echt, G., Leon, W., Shah, R., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00503-8 · Cited by 112
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01863-0 · Cited by 94
Recent advances in understanding idiopathic pulmonary fibrosis
Daccord, C., & Maher, T. M. (2016) · F1000Research · doi:10.12688/f1000research.8209.1 · Cited by 91
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis
Shea, B. S., Probst, C. K., Brazee, P. L., Rotile, N. J., Blasi, F., Weinreb, P. H., Black, K. E., Sosnovik, D. E., Cott, E. M. V., Violette, S. M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.86608 · Cited by 84
Self-citationBexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0636oc · Cited by 80
Self-citationIntegrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
Maher, T. M., Simpson, J. K., Porter, J. C., Wilson, F. J., Chan, R. H., Eames, R., Cui, Y., Siederer, S. K., Parry, S., Kenny, J. D., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01339-7 · Cited by 73
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis
Oldham, J. M., Huang, Y., Bose, S., Ma, S.-F., Kim, J. S., Schwab, A., Ting, C., Mou, K., Lee, C. T., Adegunsoye, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202301-0117oc · Cited by 72
Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis
Fabrellas, E. F., Sánchez, R. P., Abad, C. S., & Samper, G. J. (2018) · Medical Sciences · doi:10.3390/medsci6020051 · Cited by 69
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martínez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 69
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 66
Maden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2435-3 · Cited by 66
Lukey, P. T., Coello, C. S., Gunn, R. N., Parker, C. A., Wilson, F. J., Saleem, A., Garman, N., Costa, M. J., Kendrick, S. F. W., Onega, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04586-z · Cited by 64
Self-citationSurolia, R., Li, F. J., Wang, Z., Li, H., Liu, G., Zhou, Y., Luckhardt, T., Bae, S., Liu, R.-M., Rangarajan, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91377 · Cited by 63
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis
Tatler, A. L., Goodwin, A. T., Gbolahan, O., Saini, G., Porte, J., John, A. E., Clifford, R. L., Violette, S. M., Weinreb, P. H., Parfrey, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158047 · Cited by 52
Self-citationRoach, K. M., Sutcliffe, A., Matthews, L., Elliott, G., Newby, C., Amrani, Y., & Bradding, P. (2018) · Scientific Reports · doi:10.1038/s41598-017-18555-9 · Cited by 51
De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8
Roy, A., Shi, L., Chang, A., Dong, X., Fernandez, A. N., Kraft, J. C., Li, J., Le, V. Q., Winegar, R. V., Cherf, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41272-z · Cited by 52
Novel drug targets for idiopathic pulmonary fibrosis
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1152186 · Cited by 43
Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis
Hasan, M., Paul, N. C., Paul, S. K., Saikat, A. S. M., Akter, H., Mandal, M., & Lee, S. (2022) · Molecules · doi:10.3390/molecules27051481 · Cited by 42
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis
Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1553620 · Cited by 37
COVID-19 and acute exacerbation of interstitial lung disease
Kondoh, Y., Kataoka, K., Ando, M., Awaya, Y., Ichikado, K., Kataoka, M., Komase, Y., Mineshita, M., Ohno, Y., Okamoto, H., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.06.007 · Cited by 36
Molecular Endotyping of Pulmonary Fibrosis
Goodwin, A. T., & Jenkins, G. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1511 · Cited by 33
Self-citationCell adhesion molecules in fibrotic diseases
Hu, Q., Saleem, K., Pandey, J., Charania, A. N., Zhou, Y., & He, C. (2023) · Biomedicines · doi:10.3390/biomedicines11071995 · Cited by 32
Tatler, A. L., Habgood, A., Porte, J., John, A. E., Stavrou, A., Hodge, E., Kerama-Likoko, C., Violette, S. M., Weinreb, P. H., Knox, A. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692368 · Cited by 34
Self-citationThe Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease
Karampitsakos, Τ., Tourki, B., & Herazo‐Maya, J. D. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.10.042 · Cited by 31
Keat, N., Kenny, J. D., Chen, K., Onega, M., Garman, N., Slack, R. J., Parker, C. A., Lumbers, R. T., Hallett, W., Saleem, A., et al. (2018) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.117.203547 · Cited by 31
Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options
Hewitt, R. J., & Maher, T. M. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00647-y · Cited by 32
Khanna, D., Tashkin, D. P., Wells, A. U., Seibold, J. R., Wax, S. D., Vazquez‐Mateo, C., Fleuranceau-Morel, P., Damian, D., & Denton, C. P. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.191365 · Cited by 28
Evolution and treatment of idiopathic pulmonary fibrosis
Torrisi, S. E., Kahn, N. C., Vancheri, C., & Kreuter, M. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104025 · Cited by 29
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Aryal, S., & Nathan, S. D. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1471465 · Cited by 26
Montesi, S. B., Cosgrove, G. P., Turner, S., Zhou, I. Y., Efthimiou, N., Šušnjar, A., Catana, C., Fromson, C., Clark, A., Decaris, M. L., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-1934oc · Cited by 28
Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 25
Sime, P. J., & Jenkins, G. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202208-1579ed · Cited by 24
Self-citationAdvances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 22
Tomos, I. P., Kanellopoulou, P., Nastos, D., & Aidinis, V. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2471579 · Cited by 19
The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis
Stephenson, K. E., Porte, J., Kelly, A., Wallace, W. A., Huntington, C. E. C., Overed-Sayer, C. L., Cohen, E. S., Jenkins, G. R., & John, A. E. (2023) · Respiratory Research · doi:10.1186/s12931-023-02334-4 · Cited by 20
Self-citationBalaji, S., Dong, X., Li, H., Zhang, Y., Steen, E. H., & Lingappan, K. (2018) · Physiological Genomics · doi:10.1152/physiolgenomics.00075.2018 · Cited by 20
Antibody-based therapies for idiopathic pulmonary fibrosis
Sgalla, G., Flore, M., Siciliano, M., & Richeldi, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735346 · Cited by 22
Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis
Wang, Q., Xie, Z., Wan, N., Yang, L., Jin, Z., Jin, F., Huang, Z., Chen, M., Wang, H., & Feng, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002171 · Cited by 20
Fukihara, J., & Kondoh, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.007 · Cited by 23
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
Macagno, F., Varone, F., Leone, P. M., Mari, P., Panico, L., Berardini, L., & Richeldi, L. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335601 · Cited by 19
Mooney, J. J., Jacobs, S. S., Lefebvre, E. A., Cosgrove, G. P., Clark, A., Turner, S., Decaris, M. L., Barnes, C. N., Jurek, M., Williams, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202409-969oc · Cited by 18
Mini review of first-in-human integrin αvβ6 PET tracers
Kimura, R. H., Iagaru, A. H., & Guo, H. H. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1271208 · Cited by 17
Siekacz, K., Kumor‐Kisielewska, A., Miłkowska-Dymanowska, J., Pietrusińska, M., Bartczak, K. T., Majewski, S., Stańczyk, A., Piotrowski, W. J., & Białas, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010342 · Cited by 17
Investigational drugs for idiopathic pulmonary fibrosis
Varone, F., Montemurro, G., Macagno, F., Calvello, M., Conte, E. G., Intini, E., Iovene, B., Leone, P. M., Mari, P., & Richeldi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1364361 · Cited by 15
Ligand-bound integrin αvβ6 internalisation and trafficking
Meecham, A., Cutmore, L. C., Protopapa, P., Rigby, L. G., & Marshall, J. F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.920303 · Cited by 15
Liu, H., Gao, L., Yu, X., Zhong, L., Shi, J., Jia, B., Li, N., Liu, Z., & Wang, F. (2018) · Biophysics Reports · doi:10.1007/s41048-018-0071-1 · Cited by 15
Robinson, H., Oatley, S. A., Rowedder, J. E., Slade, P., Macdonald, S. J. F., Argent, S. P., Hirst, J. D., McInally, T., & Moody, C. J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001059 · Cited by 15
Meecham, A., & Marshall, J. F. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1878143 · Cited by 15
Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions
Eriksson, O., & Velikyan, I. (2023) · Pharmaceuticals · doi:10.3390/ph16111540 · Cited by 14
Maddali, M. V., Moore, A. R., Sinha, P., Newton, C. A., Kim, J. S., Adegunsoye, A., Ma, S., Strek, M. E., Chen, C., Linderholm, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0339oc · Cited by 15
Young, O. N., Bourke, J. E., & Widdop, R. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115839 · Cited by 16
Perez-Favila, A., Veloz, I. G., Hernandez-Marquez, L. S., Gutierrez-Vela, E. F., Flores‐Morales, V., & Martínez‐Fierro, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031562 · Cited by 13
Wilkinson, A. L., John, A. E., Barrett, J. W., Gower, E., Morrison, V. S., Man, Y., Pun, K., Roper, J. A., Luckett, J., Borthwick, L. A., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174618 · Cited by 13
Self-citationBiomarkers Unveil Insights into Pathology of Transitional Epithelial States in Pulmonary Fibrosis
Ting, C., Konopka, K. E., Benedeck, R. E., Riches, D. W. H., Redente, E. F., Oldham, J. M., & Zemans, R. L. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1839le · Cited by 12
Yu, J., Qi, J., Kong, X., & Feng, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107966 · Cited by 13
Neonatal Lung Disease: Mechanisms Driving Sex Differences
Lingappan, K., Hayward-Piatkovskyi, B., & Gleghorn, J. P. (2021) · Physiology in health and disease · doi:10.1007/978-3-030-63549-7_5 · Cited by 11
αVβ6 Integrin: An Intriguing Target for COVID‐19 and Related Diseases
Bugatti, K. (2021) · ChemBioChem · doi:10.1002/cbic.202100209 · Cited by 10
Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis
Jones, N., Rahar, B., Bernau, K., Schulte, J. J., Campagnola, P. J., & Brasier, A. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115393 · Cited by 8
Clinical Trials in IPF: What Are the Best Endpoints?
Spagnolo, P., Cocconcelli, E., & Cottin, V. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_19 · Cited by 8
Onega, M., Parker, C. A., Coello, C. S., Rizzo, G., Keat, N., Ramada‐Magalhaes, J., Moz, S., Tang, S.-P., Plisson, C., Wells, L. A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04653-5 · Cited by 8
Gulhane, A. V., & Chen, D. L. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210824 · Cited by 8
Zamfir, A.-S., Zabara, M., Arcana, R. I., Cernomaz, A. T., Zabara-Antal, A., Marcu, D. T. M., Trofor, A. C., Zamfir, C. L., & Crișan-Dabija, R. A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111607 · Cited by 7
Gajjala, P. R., Singh, P., Odayar, V., Ediga, H. H., McCormack, F. X., & Madala, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032850 · Cited by 8
Froidure, A., Joannes, A., Mailleux, A., & Crestani, B. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1171140 · Cited by 7
Wuyts, W. A., LANCASTER, L. H., Maher, T. M., Ryerson, C. J., Kreuter, M., Corte, T. J., Valenzuela, C., Barnes, C. N., Lefebvre, E. A., Cosgrove, G. P., et al. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002937 · Cited by 6
Lo, W. C. Y., Boas, C. W. V., Huynh, T. T., Klaas, A., Grogan, F., Strong, L., Samson, P. P., Robinson, C. G., Rogers, B. E., & Bergom, C. R. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.08.034 · Cited by 5
Wu, H., Li, L., Xiao, Z., Chen, Q., Li, C., & He, Y. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07146-w · Cited by 5
Biomarkers in Idiopathic Pulmonary Fibrosis
Stankovic, S. D., Stjepanović, M., & Ašanin, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100042 · Cited by 5
Inchingolo, R., Condoluci, C., Smargiassi, A., Mastrobattista, A., Boccabella, C., Comes, A., Golfi, N., & Richeldi, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1383382 · Cited by 7
Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient
Jones, M. G., Walsh, S. L. F., Jones, K. D., & Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00265-2016 · Cited by 4
AN INTEGRIN RENAISSANCE: RECENT PROGRESS OF INTEGRIN MODULATORS IN THE CLINIC
Finkelstein, D. S., & Machajewski, T. D. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch08 · Cited by 3
Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
Perrotta, F., Zamparelli, S. S., D’Agnano, V., Montella, A., Fomez, R., Pagliaro, R., Schiattarella, A., Cazzola, M., Bianco, A., & Mariniello, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071384 · Cited by 4
Long COVID and Lung Involvement: A One-Year Longitudinal, Real-Life Study
Stefania, M. N., Toma, C., Bondor, C. I., Maria, R. V., Petrariu, F. D., & Man, M. A. (2025) · Medicina · doi:10.3390/medicina61020304 · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
Schott, C. A., Mohning, M. P., & Cooley, J. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2651-1937 · Cited by 2
Mawer, C. M., Stanel, S. C., Ward, E. M., Smith, D. J. F., Hull, R. C., & Mehta, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2675640 · Cited by 2
Poletti, V. E., Tomassetti, S., Ravaglia, C., Dubini, A., Piciucchi, S., Cavazza, A., & Chilosi, M. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005015 · Cited by 2
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
Pasciuto, G., Inchingolo, R., Condoluci, C., Magnini, D., Iovene, B., & Richeldi, L. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0209-0 · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
Soskis, A., & Hallowell, R. W. (2021) · Respiration · doi:10.1159/000515607 · Cited by 2
PET Molecular Imaging and Theranostics in Lung Diseases
Assadi, M., Juweid, M., Jonigk, D. D., Spillner, J. W., Rayyan, Y. M., Jarraya, H., Mottaghy, F. M., & Dweik, R. A. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.03.025 · Cited by 1
Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?
Ask, K., Hambly, N., & Kolb, M. R. J. (2015) · Current Pulmonology Reports · doi:10.1007/s13665-015-0123-7 · Cited by 1
Targeting the αv Integrins in Fibroproliferative Disease
Nanthakumar, C. B., Hatley, R. J. D., & Slack, R. J. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015783-00037 · Cited by 1
Kızılırmak, D., Karadoğan, D., Yıldırım, H., Akyıl, F. T., Eyüboğlu, T. Ş., Emiralioğlu, N., Sertçelik, Ü. Ö., Günaydın, F. E., Ataoğlu, Ö., Oguz, M. S., et al. (2022) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2022.21081 · Cited by 1
Key ongoing issues in trial design
Jones, M. G., & Richeldi, L. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006515
Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers
Anaev, E. K. (2017) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-1-56-64 · Cited by 1
Chaudhuri, N., George, P. M., Kreuter, M., Molina‐Molina, M., Rivera‐Ortega, P., Stella, G. M., Stewart, I. D., Spencer, L. G., Wells, A. U., & Jenkins, G. R. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202011-4146le
Self-citationINTEGRIS-IPF: A New Hope for Tomorrow
Wang, F., Zhu, M., & Luo, F. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202407-1295ed · Cited by 1
Farnia, P., Velayati, A. A., Ghanavi, J., & Farnia, P. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-96883-9_8
Metadata
- Authors
- Saini, G., Porte, J., Weinreb, P. H., Violette, S. M., Wallace, W. A., McKeever, T. M., & Jenkins, G.
- Affiliations
- University of Nottingham (GB)
- Biogen (United States) (US)
- University of Edinburgh (GB)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2015-03-05
- Volume
- 46
- Issue
- 2
- Pages
- 486-494
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2113575939
- Cited by
- 106
- References
- 38
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 16 · 2022: 7 · 2021: 11 · 2020: 13 · 2019: 5 · 2018: 11 · 2017: 9 · 2016: 9 · 2015: 3
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Nottingham ePrints (University of Nottingham) (submittedVersion)
- Funders
- Medical Research Council (MICA grant G0901226)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- integrin αvβ6, idiopathic pulmonary fibrosis, interstitial lung disease, prognostic factors, disease endotypes, overall survival, fibroblastic foci, alpha-smooth muscle actin, hepatocyte growth factor, tenascin-C, pulmonary fibrosis
- MeSH terms
- Adult, Aged, Antigens, Neoplasm, Biopsy, Female, Humans, Lung, Male, Middle Aged, Prognosis, Biomarkers, Integrins, Lung Diseases, Interstitial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
